Aussie Flu Vaccine Urged For Blacklisting By U.S. Panel
This article was originally published in PharmAsia News
Australia-made flu vaccines have been recommended for blacklisting by a U.S. panel, citing problems encountered with the drug in Australia and New Zealand
You may also be interested in...
US Proposed Class Action: Preservative Choice Makes Unilever’s TRESemme Keratin Products ‘Defective’
The presence of formaldehyde releaser DMDM hydantoin in TRESemme Keratin shampoos pose undisclosed risks of hair loss and/or scalp irritation, as shown by hundreds of consumer complaints online, plaintiffs allege in proposed class actions filed in Illinois and New Jersey federal courts.
Industry leaders share their expectations around COVID-19 for the coming year. Further product development and vaccine rollout will be key themes in 2021. Equitable supply and addressing the mental health challenges associated with lockdowns also loom large.
New drug development is an increasingly communal enterprise. In Vivo examines how one major US academic institution – the University of California at Los Angeles (UCLA) – is expanding its range of research contacts to open new areas of therapy and shorten the transition from bench to the bedside.